The LifeTime Initiative encompasses more than 130 medical and scientific establishments and businesses in 22 countries.

The Lifetime initiative aims to map, understand the cellular and molecular mechanism underlying the onset progression and therapy response of key diseases by developing and combining several disruptive technologies, applying them to patient samples and in the clinic.